LSD1-IN-35, identified by its CAS number 2992690-04-5, is a small molecule inhibitor specifically targeting the enzyme lysine-specific demethylase 1 (LSD1). This enzyme plays a crucial role in the regulation of gene expression through the demethylation of lysine residues on histones, impacting various biological processes, including development and differentiation. LSD1-IN-35 is characterized by its ability to selectively inhibit LSD1 activity, making it a valuable tool in research related to epigenetics and cancer biology. The compound is typically studied for its potential therapeutic applications, particularly in the context of cancers where LSD1 is overexpressed or aberrantly regulated. Its chemical structure features specific functional groups that contribute to its binding affinity and selectivity for LSD1. As with many small molecule inhibitors, the pharmacokinetics, bioavailability, and toxicity profiles are important considerations for its development as a therapeutic agent. Further research is ongoing to fully elucidate its biological effects and potential clinical applications.

LSD1-IN-35

2992690-04-5: LSD1-IN-35, identified by its CAS number 2992690-04-5, is a small molecule inhibitor specifically targeting the enzyme lysine-specific demethylase 1 (LSD1). This enzyme plays a crucial role in the regulation of gene expression through the demethylation of lysine residues on histones, impacting various biological processes, including development and differentiation. LSD1-IN-35 is characterized by its ability to selectively inhibit LSD1 activity, making it a valuable tool in research related to epigenetics and cancer biology. The compound is typically studied for its potential therapeutic applications, particularly in the context of cancers where LSD1 is overexpressed or aberrantly regulated. Its chemical structure features specific functional groups that contribute to its binding affinity and selectivity for LSD1. As with many small molecule inhibitors, the pharmacokinetics, bioavailability, and toxicity profiles are important considerations for its development as a therapeutic agent. Further research is ongoing to fully elucidate its biological effects and potential clinical applications.

<p>LSD1-IN-35 (Compound Z-1) is a selective inhibitor of LSD1, exhibiting an IC50 of 108 nM. This compound inhibits the demethylation of H3K4me1/2 and acts as an immunomodulator. Additionally, LSD1-IN-35 enhances the responsiveness of gastric cancer cells to T-cell killing by reducing PD-L1 expression, thereby weakening the PD-1/PD-L1 interaction.</p>

CAS 2992690-04-5

LSD1-IN-35

LSD1-IN-35

Ref: TM-T200691